Scarica l'app Stockscreener
32.06
13.77%
-5.12
Dopo l'orario di chiusura:
32.30
0.24
+0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$37.18
Aprire:
$36.95
Volume 24 ore:
2.89M
Relative Volume:
3.07
Capitalizzazione di mercato:
$3.53B
Reddito:
-
Utile/perdita netta:
$-804.34M
Rapporto P/E:
-3.407
EPS:
-9.41
Flusso di cassa netto:
$-531.06M
1 W Prestazione:
-9.77%
1M Prestazione:
-14.98%
6M Prestazione:
-16.01%
1 anno Prestazione:
-35.28%
Intervallo 1D:
$31.47
$36.95
Intervallo di 1 settimana:
$31.47
$38.23
Portata 52W:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
32.06 | 3.53B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven Ltd. SEC 10-K Report - TradingView
Piper Sandler maintains Biohaven stock with $76 target By Investing.com - Investing.com South Africa
Piper Sandler maintains Biohaven stock with $76 target - Investing.com India
Biohaven’s ion channel drug fails pivotal bipolar mania study - Endpoints News
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy - Benzinga
Biohaven down 10% on quarterly EPS miss, bipolar mania asset study - Seeking Alpha
Biohaven’s BHV-1300 shows promise in IgG reduction By Investing.com - Investing.com Canada
Biohaven’s BHV-1300 shows promise in IgG reduction - Investing.com
Biohaven reports ‘positive’ data from study of BHV-1300 - TipRanks
Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - Marketscreener.com
Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider.com
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha
(BHVN) Technical Pivots with Risk Controls - Stock Traders Daily
Biohaven's troriluzole gains FDA priority review for SCA - MSN
Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft - MarketBeat
Biohaven stock rises following FDA review and Deutsche Bank's buy rating - MSN
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Mississippi to receive$162.2K of $59.7M Settlement Over Alleged Biohaven Kickbacks - Vicksburg Daily News
Biohaven Ltd. Receives FDA Priority Review for Troriluzole, Boosting Investor Confidence - TipRanks
Why Biohaven Stock Triumphed on Tuesday - The Motley Fool
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
Biohaven, Ecolab, Firefly - TradingView
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha
Biohaven stock rises following FDA review and Deutsche Bank’s buy rating - Investing.com Nigeria
Biohaven stock rises following FDA review and Deutsche Bank's buy rating By Investing.com - Investing.com South Africa
Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise - Marketscreener.com
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA - TipRanks
Why Biohaven Ltd. Shares Are Tumbling? - TipRanks
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - Quantisnow
Jennison Associates LLC Makes New $3.64 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Kickback Case Settled For $59M - NewsBreak
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Attorney General’s Office secures $2.3M in multistate action from Pfizer-owned company - Florida Politics
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):